CORRECTION article

Front. Cardiovasc. Med., 21 February 2024

Sec. General Cardiovascular Medicine

Volume 11 - 2024 | https://doi.org/10.3389/fcvm.2024.1371699

Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials

  • 1. Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

  • 2. Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China

  • 3. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

  • 4. Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

  • 5. Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

  • 6. Respiratory Department, The Affiliated Hospital of Qingdao University, Qingdao, China

  • 7. Department of Cardiology, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing, China

  • 8. Congenital Heart Disease Center, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, China

Article metrics

View details

1,4k

Views

586

Downloads

Incorrect Funding

In the published article, there was an error in the Funding statement.

There was an error in specifying the grant number of National Natural Science Foundation of China (CN) in the Funding section of the paper. The correct grant number is [81970047] and [82270050], but it was mistakenly written as [81800047].

The original text was: This work was supported by the National Natural Science Foundation of China (CN) (81800047) and the Clinical Research Innovation and Incubation Foundation of Renji Hospital, Shanghai Jiao Tong University School of Medicine (PYII20-13).

The correct Funding statement appears below.

Statements

Funding

This work was supported by the National Natural Science Foundation of China (CN) (81970047, 82270050) and the Clinical Research Innovation and Incubation Foundation of Renji Hospital, Shanghai Jiao Tong University School of Medicine (PYII20-13).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

pulmonary arterial hypertension, time to clinical improvement, efficacy, risk stratification, 6-min walk distance

Citation

Wang A, Chen M, Zhuang Q, Guan L, Xie W, Wang L, Huang W, Cheng Z, Yu S, Zhou H and Shen J (2024) Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials. Front. Cardiovasc. Med. 11:1371699. doi: 10.3389/fcvm.2024.1371699

Received

16 January 2024

Accepted

18 January 2024

Published

21 February 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

11 - 2024

Updates

Copyright

*Correspondence: Jieyan Shen

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics